GMAB
Genmab A/SBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
Current thesis
Genmab is still growing on the back of DARZALEX/Kesimpta royalties and EPKINLY sales, while the late-stage Rina-S and petosemtamab programs plus ASCO/EHA visibility keep multiple shots on goal alive.
Posture
Constructive
Lead driver
Sentiment
What changed
1 setup hits (3d) with net bearish as of 2026-06-02.
What can break
Concentration risk remains high because current growth is still heavily reliant on DARZALEX and Kesimpta royalties plus EPKINLY uptake.
Momentum
28
Value
64
Sentiment
92
Setup hits (3d)
1 · Net Bearish
AI TargetsBase $36.86 · Bull $44.00 · Bear $21.00
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-06-01 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
As of 2026-05-28 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-06-02
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade B · Constructive
Confidence Medium · Net Bearish
Target $36.86
Why
Momentum28 · Δ7d +6.2
Value64 · Δ7d +0.5
Sentiment92 · Δ7d -3.1
So what
Strength-led posture (Net Bearish). Favor watchlist adds and disciplined entries.
Lead driver: Sentiment · See AI snapshot
Momentum
28
34% active weight
Current posture
7d trendImproving
Δ7d
+6.2
Δ21d
+7.2
Value
64
32% active weight
Current posture
7d trendFlat
Δ7d
+0.5
Δ21d
+0.7
Sentiment
92
33% active weight
Current posture
7d trendSoftening
Δ7d
-3.1
Δ21d
-0.4
Why this grade
Composite grade B. Momentum 27.6 / Value 63.9 / Sentiment 91.6
Fundamentals (TTM)As of 2026-06-01
Fundamentals (TTM)
As of 2026-06-01
Market Cap
$15.23B
Beta
0.76
Shares Out
61.6M
P/E (TTM)
13.4
P/S (TTM)
5.65
P/FCF (TTM)
16.83
Rev YoY
+25.2%
EPS YoY
+121.3%
Gross Margin
+94.3%
Op Margin
+36.7%
Net Debt
-$2.79B
Current Ratio
6.03
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology